Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

Abstract Background Olipudase alfa is a recombinant human acid sphingomyelinase enzyme replacement therapy for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD). The ASCEND randomized placebo-controlled trial in adults with ASMD demonstrated reductions in sphingomy...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Melissa P. Wasserstein, Robin Lachmann, Carla Hollak, Antonio Barbato, Renata C. Gallagher, Roberto Giugliani, Norberto Bernardo Guelbert, Julia B. Hennermann, Takayuki Ikezoe, Olivier Lidove, Paulina Mabe, Eugen Mengel, Maurizio Scarpa, Ebubekir Senates, Michel Tchan, Jesus Villarrubia, Beth L. Thurberg, Abhimanyu Yarramaneni, Nicole M. Armstrong, Yong Kim, Monica Kumar
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2023-12-01
Saila:	Orphanet Journal of Rare Diseases
Gaiak:	Recombinant human acid sphingomyelinase Dose escalation Organomegaly Lung diffusing capacity Acid sphingomyelinase deficiency Niemann–Pick type B
Sarrera elektronikoa:	https://doi.org/10.1186/s13023-023-02983-0
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!